![](https://monteverdelaw.com/wp-content/uploads/case-logo/karuna-therapeutics-inc.png)
Karuna Therapeutics, Inc. (Nasdaq: KRTX), relating to its proposed sale to Bristol Myers Squibb. Under the terms of the agreement, KRTX shareholders will receive $330.00 in cash per share they own.
Karuna Therapeutics, Inc. (Nasdaq: KRTX), relating to its proposed sale to Bristol Myers Squibb. Under the terms of the agreement, KRTX shareholders will receive $330.00 in cash per share they own.